Viatris Komárom-Mylan Hungary to Expand Capacity

US-owned pharmaceutical company Viatris Komárom-Mylan Hungary will invest over EUR 16 million at its base in Komárom (northwest of Budapest), expanding packaging and quality control capacity.

Mylan Hungary Ltd., part of the American Viatris group, is one of the key centers in the European packaging and quality control network. At its Komárom site, the company primarily focuses on packaging tablets and capsules, and it also houses one of the largest pharmaceutical testing and market authorization laboratories in the European Union.

The company is expanding its packaging and quality control capacities with a €16.33 million investment, ensuring increased production volume and more efficient operations. As a result of the development, annual packaging capacity will rise from 140 million to 165 million units, significantly contributing to faster and more reliable access to medicines. The project will create 12 new jobs, primarily in production and quality control.

Most of the production is directed to export markets, primarily Western Europe, making the company's activities play an important role in Hungary's export performance and the stability of pharmaceutical supply in Europe.

As part of the investment, energy efficiency improvements will also be implemented: the installation of a solar power system and heat pump technology will enhance energy efficiency, promote sustainability, and reduce environmental impact.

The pharmaceutical industry is one of the most dynamic and innovative sectors of the Hungarian economy. The operation of the Komárom site plays a crucial role in further strengthening Hungary’s position in the European pharmaceutical supply chain and maintaining the sector’s competitiveness.